Companies: 10,795·Total market cap: $144.5T
Albireo Pharma, Inc.

Albireo Pharma, Inc.

ALBONASDAQHealthcare
$44.15
+$0.00(+0.00%)
Market Cap$915887335
P/E Ratio
52W High$45.23
52W Low$16.02
SEC Filings

Albireo Pharma, Inc. (ALBO) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001322505 · ALBO · NASDAQ · as of Jun 8, 2026

Filing snapshot

1,001+
Total Filings
SC 13G/A
Latest Form
2024-02-14
Most Recent
2007
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001322505 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2022-03-01
Fiscal Year End
Mar 1, 2022
Accession No.
0001558370-22-002501
Primary Document
albo-20211231x10k.htm
Source: data.sec.gov · CIK 0001322505 · Accession 0001558370-22-002501

Latest Key Filings

10-QQuarterly Report
10-Q
2022-11-08
8-KCurrent Report
FORM 8-K
2023-03-02Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2024-02-14
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2023-04-10
View
15-12G15-12G
15-12G
2023-03-14
View
EFFECTEFFECT
EFFECT
2023-03-08
View
EFFECTEFFECT
EFFECT
2023-03-08
View
EFFECTEFFECT
EFFECT
2023-03-08
View
EFFECTEFFECT
EFFECT
2023-03-08
View
EFFECTEFFECT
EFFECT
2023-03-08
View
SC 13G/ABeneficial Ownership Report (Amended)
Beneficial Ownership Report (Amended)
2023-03-08
View
S-8 POSS-8 POS
S-8 POS
2023-03-02
View
S-8 POSS-8 POS
S-8 POS
2023-03-02
View
S-8 POSS-8 POS
S-8 POS
2023-03-02
View
S-8 POSS-8 POS
S-8 POS
2023-03-02
View
S-8 POSS-8 POS
S-8 POS
2023-03-02
View
POS AMPOS AM
POS AM
2023-03-02
View
Showing 1–15 of 546 filingsForm 4 / 144 hidden· 1001 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001322505  |  Exchange: NASDAQ · Healthcare

Albireo Pharma, Inc. (NASDAQ: ALBO) has submitted 1,001+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2007. As a Healthcare sector company with CIK 0001322505, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Albireo Pharma, Inc.'s most comprehensive regulatory disclosure. The most recent Albireo Pharma, Inc. 10-K was filed on 2022-03-01 for fiscal year ending 2022. Historical ALBO 10-K annual reports are available from 2009 through 2022.

Investors researching Albireo Pharma, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

ALBO SEC Filings · 8 questions

Albireo Pharma, Inc. (ALBO) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,001+ filings and access original documents at no cost. Albireo Pharma, Inc.'s CIK is 0001322505.

ALBO SEC filingsAlbireo Pharma, Inc. SEC documentsfind ALBO 10-K